Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer

Final draft guidance

Final draft guidance (PDF 150 KB)

Committee papers - FDG (PDF 2.43 MB)

Final scope (PDF 130 KB)

Equality impact assessment (scoping) (PDF 104 KB)

Draft matrix post referral (PDF 119 KB)

Final appraisal document TA721 (PDF 319 KB)

Public committee slides TA721 (PDF 1.12 MB)

Appeal letter BUG TA721 : Appeal letter (MSWord 226 KB)

Appeal letter Janssen TA721 : Appeal letter (MSWord 62 KB)

Appeal letter TPC/PCUK TA721 : Appeal letter (MSWord 1.17 MB)

Scrutiny letter Janssen TA721 : Scrutiny letter (MSWord 65 KB)

Scrutiny letter BUG TA721 : Scrutiny letter (MSWord 64 KB)

Scrutiny letter TPC/PCUK TA721 : Scrutiny letter (MSWord 63 KB)

Response to scrutiny letter BUG TA721 : Response to scrutiny letter (MSWord 119 KB)

Response to scrutiny letter Janssen TA721 : Response to scrutiny letter (MSWord 631 KB)

Response to scrutiny letter BUG/NHSE TA721 : Response to scrutiny letter (MSWord 173 KB)

Final scrutiny letter BUG TA721 : Final scrutiny letter (MSWord 68 KB)

Final scrutiny letter Janssen TA721 : Final scrutiny letter (MSWord 66 KB)

Final appraisal document TA721 (PDF 290 KB)

Committee papers TA721 TA721 (PDF 3.98 MB)

Public committee slides TA721 (PDF 1.69 MB)

Draft guidance (downloadable version) TA721 (PDF 364 KB)

Committee papers TA721 (PDF 3.99 MB)

Final scope - TA721 (PDF 85 KB)

Final stakeholder list TA721 (PDF 304 KB)

NICE's response to comments on the draft scope and provisional stakeholder list TA721 (MSWord 33 KB)